PS-341 [Bortezomib]

Proteasome inhibitors: a novel class of potent and effective antitumor agents: J. Adams, et al.; Cancer Res. 59, 2615 (1999) | Development of the proteasome inhibitor Velcade (Bortezomib): J. Adams & M. Kauffmann; Cancer Invest. 22, 304 (2004) | Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells: S.T. Nawrocki, et al.; Cancer Res. 65, 11510 (2005) | A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib: D. Chauhan, et al.; Cancer Cell 8, 407 (2005) | Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate: A.F. Kisselev, et al.; J. Biol. Chem. 281, 8582 (2006) | Bortezomib interactions with chemotherapy agents in acute leukemia in vitro: T.M. Horton, et al.; Cancer Chemother. Pharmacol. 58, 13 (2006) | Bortezomib as an antitumor agent: A.M. Roccaro, et al.; Curr. Pharm. Biotechnol. 7, 441 (2006) (Review) | Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib: A. Kardosh, et al.; Cancer Res. 68, 843 (2008) | Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation: C. Li, et al.; J. Biol. Chem. 285, 16096 (2010) | Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis: M. Hirai, et al.; Blood 117, 500 (2011) | Bortezomib, a proteasome inhibitor, attenuates angiotensin II-induced hypertension and aortic remodeling in rats: S. Li, et al; PLoS One 8, e78564 (2013) | Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells: H. Min, et al.; Cancer Chemother. Pharmacol. 74, 167 (2014) | Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the VCAM-1/VLA-4 axis: A. Ghobadi, et al.; Blood 124, 2752 (2014) | Bortezomib inhibits C2C12 growth by inducing cell cycle arrest and apoptosis: S.S. Xing, et al.; BBRC 445, 375 (2014) | Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2: Z. Wang, et al.; Int. J. Oncol. 45, 1469 (2014) | Efficient apoptosis and necrosis induction by proteasome inhibitor: bortezomib in the DLD-1 human colon cancer cell line: R. Kr?towski, et al.; Mol. Cell Biochem. 398, 165 (2015) | Live cell, image-based high-throughput screen to quantitate p53 stabilization and viability in human papillomavirus positive cancer cells: G. Martinez-Noel, et al.; Virology 560, 96 (2021)